AI assistant
REGENXBIO Inc. — Director's Dealing 2026
Jan 29, 2026
32827_dirs_2026-01-29_b509b99d-6d71-4993-92c2-dcead081c195.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENXBIO Inc. (RGNX)
CIK: 0001590877
Period of Report: 2026-01-27
Reporting Person: Mills Kenneth T. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-27 | Common Stock | M | 225000.00 | $13.09 | Acquired | 707871.00 | Direct |
| 2026-01-27 | Common Stock | F | 221753.00 | $13.41 | Disposed | 486118.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-27 | Stock Options (Right to Buy) | $13.09 | M | 225000.00 | Disposed | 2026-01-28 | Common Stock (225000.00) | Direct |
Footnotes
F1: The previously granted option, representing a right to purchase a total of 225,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter.
F2: Represents shares of common stock withheld to satisfy the exercise price and pay taxes upon the exercise of options originally granted to the reporting person on January 28, 2016, which were set to expire on January 28, 2026. The number of shares withheld was determined based on the closing price of the issuer's common stock on January 27, 2026. The transaction did not involve any open-market sale of securities.